YingBaiRui Secures Nearly RMB 100 Million in Series A+ Financing to Advance Pioneering Off-the-Shelf NK Cell Therapies
iMBioRay
CAR-NK Cell Therapy Drug Developer
TAILONG VC
Biopharmaceutical Industry Investment Institutions
Click the image to register for free2025 IBI EXPO
January 21, 2025
eMedClub News
Against the backdrop of the vigorous development of the biopharmaceutical industry，Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Imbioray") has recently completed a nearly 100-million-yuan financing round at Series A+.。This round of financing was led byLed by Zhejiang Sinowisdom Capital Co., Ltd., with participation from TAILONG VC, Imbioray, Shanghai Yuntong Medical Invest Management LTD.CO, and Binjiang 5050 Fund.The press release pointed out that the funds from this round of financing will be mainly used to advance the registration and clinical projects of global FIC (first-in-class) universal natural killer cell therapies, namely IBR854, IBR733, IBR822, IBR900, and other Class I innovative biologics. This will accelerate a series of pioneering innovations in off-the-shelf universal immune-tolerant NK/CAR-raNK therapies derived from peripheral blood, non-viral vectors, and non-gene editing technologies.®And tiNK®Cell Product Launch.
Zhejiang Sinowisdom Capital Co., Ltd.'s biomedical team has profound insights into the development of the cell therapy field, noting that "Cell-based drugs represent the third revolution in human disease treatment following vaccines and antibiotics, fundamentally addressing the root cause of diseases in the human body—cellular aging and dysfunction.In recent years, there have been continuous public clinical cases showing that cell therapy has the potential to completely cure complex and difficult diseases, with the treatment scope constantly expanding. CAR-T cell drugs have already demonstrated excellent clinical efficacy in the field of hematologic tumors.New-generation cell therapies represented by NK/CAR-NK are expected to achieve greater clinical application value in tumors (hematologic and solid tumors), autoimmune diseases, chronic diseases, CNS, and other non-tumor diseases, while enabling off-the-shelf, universal use.". We look forward to imbioray, with patient needs at its core and clinical value as its guide, becoming a global leader in NK cell immunotherapy."
Since its Pre-A round of financing, Imbioray has undergone four technological iterations, achieving the largest-scale NK cell culture with international standards and the most advanced manufacturing process (100L). This is based on four proprietary technology platforms (CAR-raNK).®- ADC-based CAR introduction platform, tiNK®- Immune-tolerant NK Cell Platform, ANKERTM-The NK connector platform directed by antibodies and the mRNA vaccine technology platform have achieved dual breakthroughs in product technology and production processes.
Based on proprietary antibody-conjugated NK cell platform technologyDeveloped more than 10 international original product pipelines with global FIC competitivenessAmong them, IBR854, the world’s first CAR-NK cell therapy targeting the 5T4 antigen for the treatment of advanced solid tumors, is about to enter Phase II clinical trials; IBR733, the world’s first and fastest-progressing CAR-NK cell therapy targeting the CD33/CLL1 dual antigens for the treatment of acute myeloid leukemia, has entered the third dosing cohort stage of Phase I clinical trials; IBR822, the world’s first CAR-NK cell therapy targeting Trop-2 for the treatment of advanced solid tumors, has entered Phase I clinical trials; and IBR900, an immune-tolerant NK cell therapy, received implied permission for clinical trials from the CDE in September 2024.
Imbioray stated,Currently, the company owns a 1,800-square-meter office building with fully informatized office management, a 3,200-square-meter standalone GMP workshop and laboratory of the highest standards, and globally leading experimental instruments and production equipment, capable of meeting a commercial production scale of 50,000 formulations per year.
At the same time, the company won the First Prize of the 12th Golden Bridge Award Project by the China Technology Market Association. It is the leading unit in formulating the national group standard "Specification for the Preparation and Release Testing of Human Natural Killer Cell Preparations" (T/CEAC 022—2024), the deputy leading unit in formulating the national group standard "Technical Requirements for Raw Material Collection in Cell Therapy Leakopak and Immune Cell Separation" (T/CEAC 069—2024), and the chief editorial unit in formulating the national group standard "Technical Specification for Clinical Application of NK Cell Therapy" (T/ZGCIT-110-2024). The company has consecutively received honors such as EBC's "Top 100 Innovations and Breakthroughs in China," "Hangzhou Unicorn and Quasi-Unicorn," "Top 10 Most Growth-Oriented Companies in China's Cell and Gene Industry," "Demonstration Unit Award for Scientific and Technological Innovation in Chinese Modernization," and "Zhejiang Province Specialized, Refined, Unique, and Innovative Small and Medium Enterprises."
Cellular medicine represents the third revolution in the treatment of human diseases, addressing the root causes of diseases in the human body. Next-generation cellular medicines, represented by NK/CAR-NK, are expected to achieve greater clinical application value in tumors, autoimmune diseases, chronic conditions, CNS, and other non-tumor diseases, while enabling off-the-shelf, universal use.To further explore the industrialization pain points currently faced by the industry and promote common development. Yima GuestThe 2025 IBI EXPO Biopharmaceutical Innovation Industry Conference will be held in Suzhou on March 1-2, 2025, where the "4th Universal Cell Drug Development Forum" will take place, featuring thematic presentations on topics such as "CMC Strategies in the Development of Non-Gene-Modified NK Cell Therapies.". This conference will invite pioneers and leaders in the field, focus on the latest research trends and advancements, and deeply discuss and look forward to future developments.NK/CAR-NK Cell TherapyFuture Development Trends. Everyone is welcome to register for the conference.
About Zhejiang Sinowisdom Capital Co., Ltd.
Swipe up to view
SINOWISDOM was founded in 2002 and is one of the earliest privately-owned venture capital investment institutions established in China, managing more than 50 venture capital funds with cumulative investments exceeding 15 billion yuan.For twenty-two years, Zhejiang Sinowisdom Capital has firmly believed that industry is the mother of wealth. It has adhered to an industry chain investment strategy and persisted in an "investment + service" model. Faithfully fulfilling its venture capital mission of investing early, small, and in technology, it continuously seeks uniqueness while focusing on hard technology fields such as information technology (including integrated circuits), energy technology, materials technology, and biotechnology. The firm has taken root in Zhejiang and deeply cultivated the Yangtze River Delta region.Under its umbrella, 35 invested companies such as Zhefu Co., Ltd., Crystal Photoelectric, Zanyu Technology, Chinese All Online, Ancad, Inventronics, Caitong Securities, Zhongxin Fluorochemical Materials, Wand Technology, Windey, Leadshine, Jintian Copper, Double Gun Technology, StarPower Semiconductor, OBiO Technology, YC Tech, Giantec Semiconductor, Powin Energy, Poly & Union Material, Jiehua Technology, and Zooming Optical have successfully gone public through IPOs. Additionally, 15 invested companies like Jinfan Biochemical, Zhangwei Technology, Daor Biotech, Blue Sky Environmental Protection, and Tianchuang Environmental Protection have achieved listings via mergers and acquisitions. Multiple other invested enterprises, including ScanTech, have passed the review for IPO, while a large number of invested companies have entered the listing coaching phase or filed for listing.Strategic Investment in Hu Qing Yu Tang to Build a Leading New Traditional Chinese Medicine Industry.Established Sinowisdom New Energy Industry, strategically investing in various types of new energy stations.At the same time, Zhejiang Sinowisdom Capital Co., Ltd. pays close attention to the transformation and upgrading of regional economies, using funds to boost local economic investment attraction, and actively implementing a cultivation plan for future industry stars in regional economies.Zhejiang Sinowisdom Capital Co., Ltd. has been awarded for many years as one of the Top 50 Best Venture Capital Institutions in China by CVSource (28), Top 20 Best Domestic Venture Capital Institutions in China, Top 30 Best Investment Institutions in Advanced Manufacturing, Top 20 RMB Funds, Top 20 Best General Partners (GP) in Hangzhou, Top 20 Best Investment Institutions in China's Carbon Neutral Industry, Top 50 Best Venture Capital Institutions by Zero2IPO (31), Top 10 Best Local Venture Capital Institutions in China, Top 50 Best Venture Capital Institutions by China Venture (31), Best Investment Institution in Advanced Manufacturing in China, Best Investment Institution in China's Medical Device Field, Top 50 Best Venture Capital Institutions by Securities Times, Annual Outstanding VC Institution, Annual Exit Institution, Top 10 Best Hard Technology Investment Institutions on the STAR Market 2023, Top 50 Best Venture Capital Institutions on the Specialized and Innovative List (13), Top 30 Best Venture Capital Institutions by Forbes, Top-tier Venture Capital Institutions by Interface, Top 10 Risk Investment Institutions in Zhejiang by the Golden Mango Award, Evergreen Investment Institution in the Yangtze River Delta, Most Trusted Investment Institution by Zhejiang Entrepreneurs, Decade Meritorious Award by Zhejiang Entrepreneurs, and Top 20 Hangzhou Municipal Fund.Chairman Zong Peimin has been consecutively selected for multiple years as one of the Top 50 Best Investors in China by Zero2IPO, Top 100 Investors in the investment industry, Top 50 Best Investors by China Finance, Outstanding Venture Capitalist and Investor of the Year by Securities Times, Best Venture Capitalist by Forbes, Top-tier Venture Capitalist by Interface, Annual Investment Leader by the Golden Mango Awards, Annual Venture Capital Figure by the China Investment Association, Annual Investment Figure at the Everything Grows Conference, and among the Top 60 Unicorn Hunters in China's Future.
About TAILONG VC
TAILONG VC was founded in 2021 as a professional equity investment management institution focused on the biopharmaceutical, medical device, and broader healthcare sectors, with a fund management scale of 20 billion RMB. TAILONG VC has a professional and experienced investment team that prioritizes investments in biopharmaceuticals, innovative medical devices, core CXO services and innovative fields, and outstanding biopharmaceutical industry funds, striving to build a science-driven, cross-cycle value investment platform for the biopharmaceutical industry.
About Grandson Technology
Sunzi Technology is a Contract Research Organization (CRO) that provides professional and comprehensive services to medical-related enterprises both in China and internationally. With offices in multiple locations such as Hangzhou, Nanjing, and Shanghai, the company focuses on clinical research services, offering international quality standards and efficient solutions that comply with ICH-GCP and Chinese GCP requirements for pharmaceutical enterprises both domestically and abroad. Specializing in clinical research across Europe, the United States, Japan, and other regions inside and outside of China, Sunzi Technology has established complete and compliant bilingual (Chinese and English) SOPs covering data management, statistics, medicine, pharmacovigilance, and clinical operations. The company drives innovation in drugs, medical devices, and in vitro diagnostic reagents while providing full-scale clinical research services. It also strategically collaborates with regulatory reviewers, various central institutions, ethics committees, and departments to promote high-quality project completion, ensuring patients have timely access to appropriate medical products.
Click the image to view the detailed schedule
About Huayi Capital
Huayi Capital is a representative institution in China that focuses on quantitative evaluation investment in the primary market of the healthcare and large health industry. It currently has nine registered funds with a management scale of nearly 8 billion yuan. Huayi Capital is a research-driven investment institution, owning the only medical investment research institute in China — Huayi Research Institute — which defines the panoramic view of domestic medical investment. Yiyun Technology serves as Huayi's post-investment management platform, dedicated to profiling and evaluating domestic healthcare and large health enterprises using quantitative models.
About "5050" Fund
The "5050" Fund is the first equity investment fund in Binjiang District directly managed by a fund management company under the High-Tech Financial Investment Group. With a total scale of 100 million yuan, the fund focuses on providing investment and financing services to seed-stage and early-stage talent enterprises, further broadening the financing channels for startups. The "5050" Talent Fund adheres to the strategy of investing early, small, and in hard-tech sectors, and has so far invested in nine biopharmaceutical companies. At the same time, it actively connects with social capital, aiming to leverage the role of government industrial funds to jointly support the early development of biopharmaceutical enterprises in our district.
About imbioray
Swipe up to view
Imbioray is a clinical-stage and venture capital-backed innovative biopharmaceutical company primarily focused on the development of cutting-edge immuno-oncology therapies and innovative drugs for non-oncology immunotherapies targeting immune-related diseases, chronic conditions, and CNS disorders. Dr. Zhenwei Miao, the founder of Imbioray, returned to China in 2016 to establish the company, setting the direction for developing off-the-shelf NK cell-based therapeutics. Imbioray has four internationally unique core technology platforms that accelerate its original innovations and possess advanced processes for large-scale in vitro closed-system NK cell culture. Based on its proprietary antibody-conjugated NK cell platform technology, Imbioray has developed multiple off-the-shelf cell therapy products, including IBR854, IBR733, and IBR822. Currently, IBR854, the world's first cell injection for advanced solid tumors, is about to enter Phase II clinical trials. IBR733, the world’s first cell injection for acute myeloid leukemia, has entered the third dose cohort stage of Phase I clinical trials. IBR822, an antibody-NK cell conjugate drug targeting advanced solid tumors, became Imbioray's third product to enter Phase I clinical trials in September this year. IBR900, Imbioray’s fourth off-the-shelf NK cell product to receive clinical trial authorization from the CDE, targets patients aged 65 and above with B-cell lymphoma or those who are intolerant to or have failed existing treatments. Imbioray also has several other NK cell products at different stages of development.
Imbioray is committed to becoming a pioneer and leader in the global NK cell immunotherapy field, with a focus on patient needs at its core and clinical value as its orientation. Adhering to the concept of "The Light of Immunotherapy, Igniting New Hope for Life,"
Welcome everyone to register for the 2025 IBI EXPO conference and move forward with the times. Below is the 2024 IBI EXPO.Video Highlights of the Event.
Registration and Event Consultation
IBI EXPO 2025 (3rd) Biomedical Innovation ConferenceWill beMarch 1, 2025 to March 2, 2025InSuzhou International Expo CenterGrandly held. The theme of the conference isCollaboratively Building the Entire Chain, Innovating and Transforming the New Ecosystem。
The conference will invite300+Guest Speaker, Opening30+Forum events, covering hundreds of hot topics, aroundCell and Gene Therapy, Radiopharmaceuticals, Antibody Innovative Conjugation, Targeted Protein Degradation, Stem Cell Regeneration, mRNA Vaccines and Nucleic Acid Drugs, Exosomesetc.New Molecular Drugs,AI Drug Discovery, Organoids, Novel Delivery Vehiclesetc.Cutting-edge Technology，Engage in exchange and discussion, and collaboratePharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsWith the efforts of multiple parties, cutting-edge innovations are being transformed from scientific research to industrial applications, injecting developmental momentum into the biopharmaceutical market.
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media:Teacher Wang 18717836231
DianDian "Share”、“Like"and"In Progress", charge me up a bit~"